UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $370.37 Million Stock Position in Cencora, Inc. (NYSE:COR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,648,451 shares of the company's stock after buying an additional 96,238 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.85% of Cencora worth $370,374,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Waverly Advisors LLC bought a new stake in shares of Cencora during the fourth quarter valued at approximately $232,000. Worldquant Millennium Advisors LLC raised its stake in Cencora by 42.4% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 385,759 shares of the company's stock valued at $86,672,000 after acquiring an additional 114,806 shares in the last quarter. iSAM Funds UK Ltd bought a new stake in Cencora during the 4th quarter valued at $1,113,000. Triglav Skladi D.O.O. acquired a new position in Cencora during the 4th quarter worth $3,640,000. Finally, Twinbeech Capital LP bought a new position in shares of Cencora in the fourth quarter worth $12,929,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Shares of COR traded up $0.65 during mid-day trading on Tuesday, hitting $293.00. The company's stock had a trading volume of 444,945 shares, compared to its average volume of 1,541,953. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a 50-day moving average price of $282.95 and a 200 day moving average price of $257.50. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35. The stock has a market capitalization of $56.79 billion, a price-to-earnings ratio of 41.65, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.80 earnings per share. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio is presently 25.52%.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. This trade represents a 8.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,223 shares of company stock worth $12,369,767 in the last three months. 10.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent analyst reports. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. UBS Group raised their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Finally, Citigroup raised their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.